Shares of Integra Lifesciences IART remained unaffected after the company reported Q3 results.
Quarterly Results
Earnings per share were up 17.65% year over year to $0.80, which beat the estimate of $0.53.
Revenue of $370,232,000 declined by 2.34% from the same period last year, which beat the estimate of $347,980,000.
Looking Ahead
Integra Lifesciences hasn't issued any earnings guidance for the time being.
Integra Lifesciences hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Oct 28, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/wzveg3um
Price Action
Company's 52-week high was at $63.23
52-week low: $34.21
Price action over last quarter: down 9.03%
Company Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and orthopedics and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra earns approximately 29% of sales internationally, with the remainder 71% derived from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.